Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients

Abstract

Background:Prostate cancer cell growth is dependent upon androgen receptor (AR) activation, which is regulated by specific kinases. The aim of the current study is to establish if AR phosphorylation by Cdk1 or ERK1/2 is of prognostic significance.Methods:Scansite 2.0 was utilised to predict which AR sites are phosphorylated by Cdk1 and ERK1/2. Immunohistochemistry for these sites was then performed on 90 hormone-naive prostate cancer specimens. The interaction between Cdk1/ERK1/2 and AR phosphorylation was investigated in vitro using LNCaP cells.Results:Phosphorylation of AR at serine 515 (pARS515) and PSA at diagnosis were independently associated with decreased time to biochemical relapse. Cdk1 and pCdk1161, but not ERK1/2, correlated with pARS515. High expression of pARS515 in patients with a PSA at diagnosis of ⩽20 ng ml−1 was associated with shorter time to biochemical relapse (P=0.019). This translated into a reduction in disease-specific survival (10-year survival, 38.1% vs 100%, P<0.001). In vitro studies demonstrated that treatment with Roscovitine (a Cdk inhibitor) caused a reduction in pCdk1161 expression, pARS515expression and cellular proliferation.Conclusion:In prostate cancer patients with PSA at diagnosis of ⩽20 ng ml−1, phosphorylation of AR at serine 515 by Cdk1 may be an independent prognostic marker.

Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells

“…In addition, the level of pAR S515 was related with EGF-induced PCa cell growth 41. pAR S515 was also proved to be a potential predictive marker for relapse in PCa 42. These studies indicated that pAR S515 is related to PCa progression.…”

Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression

“…It is interesting to note that no enrichment of ensemble peaks at EZH2-repressed genes was observed. Among these EZH2-activated genes, several have been indicated to play critical roles in cancer progression, such as ATAD2 (23), CDK1 (24) and FOXM1 (25). In prostate cancer patient samples (26), these signature genes are significantly upregulated in the metastatic prostate tumors comparing to the primary cancer samples (Fig.…”

Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects

“…95). There are many examples of serine/threonine and tyrosine kinases implicated in AR phosphorylation and amongst the most interesting are Aurora kinase A (Aurora-A), 96 cyclin-dependent kinase 1 (Cdk1), 97,98 PIM1 kinase, 99 Src and Ack1; 100–102 all of these are targets of small molecule inhibitors in clinical development.…”